Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE Studies
- James R. Klinger
- , Hikmet Al-Hiti
- , Sung A. Chang
- , Hyuk J. Chang
- , Hossein Ardeschir Ghofrani
- , Ekkehard Grünig
- , Marius M. Hoeper
- , Pavel Jansa
- , Jaquelina Ota-Arakaki
- , Tomas Pulido
- , Gérald Simonneau
- , Carmine Dario Vizza
- , Claudia Rahner
- , Christian Meier
- , Gisela Meyer
- Brown University
- Institute for Clinical and Experimental Medicine
- Yonsei University
- Justus Liebig University Giessen
- Kerckhoff Heart and Thorax Center
- Imperial College London
- Heidelberg University
- Hannover Medical School
- Charles University
- Universidade Federal de São Paulo
- National Heart Institute
- Assistance publique – Hôpitaux de Paris
- University of Rome La Sapienza
- Chrestos Concept GmbH & Co. KG
- Bayer AG
- Complexo Hospitalar da Santa Casa de Misericórdia de Porto Alegre
Research output: Contribution to journal › Article › peer-review